Allergy Therapeutics plc provided earnings guidance for the year 2021. The Group expects revenue to be £84.3 million (2020: £78.2 million) representing 8% annual growth on a reported basis and 6% on a constant currency basis, reflective of a strong performance in challenging market conditions.